(Q46213450)

20 December 2017

title

Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women (English)

1 reference

20 December 2017

lorcaserin hydrochloride hemihydrate

main subject

obesity

0 references

1 reference

ChEBI release 2020-05-28

Steven R Smith

1

1 reference

20 December 2017

Warren A Prosser

2

1 reference

20 December 2017

David J Donahue

3

1 reference

20 December 2017

Michael E Morgan

4

1 reference

20 December 2017

Christen M Anderson

5

1 reference

20 December 2017

William R Shanahan

6

1 reference

20 December 2017

APD356-004 Study Group

7

1 reference

20 December 2017

publication date

4 December 2008

1 reference

20 December 2017

published in

Obesity

1 reference

20 December 2017

volume

17

1 reference

20 December 2017

page(s)

494-503

1 reference

20 December 2017

issue

3

1 reference

20 December 2017

Cardiovascular health risks related to overweight

cites work

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.537

Weight and blood pressure. Findings in hypertension screening of 1 million Americans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.537

Multivariate correlates of adult blood pressures in nine North American populations: The Lipid Research Clinics Prevalence Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.537

The occurrence of sleep-disordered breathing among middle-aged adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.537

5-HT2C receptor agonists as potential drugs for the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.537

Regional distribution and cellular localization of 5-HT2C receptor mRNA in monkey brain: comparison with [3H]mesulergine binding sites and choline acetyltransferase mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.537

Distribution and cellular localization of the serotonin type 2C receptor messenger RNA in human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.537

Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.537

Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.537

Therapeutic and adverse actions of serotonin transporter substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.537

Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis: lessons for the future in pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.537

Valvular heart disease and the use of dopamine agonists for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.537

Dopamine agonists and the risk of cardiac-valve regurgitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.537

Drugs and valvular heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.537

Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.537

The hospital anxiety and depression scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.537

Long-term weight loss with sibutramine: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.537

Meta-analysis: pharmacologic treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.537

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.537

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.537

Early decreases in plasma lipid transfer proteins during weight reduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.537

Role of the serotonin 5-HT(2A) receptor in learning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.537

A review of central 5-HT receptors and their function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.537

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.537

Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.537

Natural history of valvular regurgitation 1 year after discontinuation of dexfenfluramine therapy. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.537

Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and doppler echocardiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.537

Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.537

Serotonin transporters, serotonin release, and the mechanism of fenfluramine neurotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.537

Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.537

The use of analogue scales in rating subjective feelings

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.537

The role of serotonin in antipsychotic drug action

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.537

31 March 2020

Identifiers

DOI

10.1038/OBY.2008.537

1 reference

20 December 2017

PubMed ID

19057523

1 reference

20 December 2017